Abstract: A process for preparing a pharmaceutical preparation consisting essentially of a lyophilized cake of cyclophosphamide monohydrate and a bulking agent which comprises freezing cyclophosphamide, a bulking agent, and water, lyophilizing part of the water, obtaining and melting a supersaturated cyclophosphamide-bulking agent solution, precipitating cyclophosphamide as a hydrated polymorph, refreezing the solution and lyophilizing the water not bound to cyclophosphamide or the bulking agent.

Abstract: A parmaceutical preparation consisting essentially of a lyophilized cake of cyclophosphamide monohydrate and lactose prepared by the process of freezing cyclophosphamide, lactose and water, lyophilizing part of the water, obtaining and melting a supersaturated cyclophosphamide-lactose solution, precipitating cyclophosphamide as a hydrated polymorph, refreezing the solution and lyophilizing the water not bound to cyclophosphamide or lactose.

Abstract: A stable rapidly dissolving lyophilized composition of cyclophosphamide and an amino acid selected from the group consisting of glycine, valine and serine is provided which contains an amount of water which is equimolar to the amount of amino acid and the amount of cyclophosphamide in said composition; the composition is preferably prepared from a solution containing at least 2% (W/V) of the amino acid and having a pH in the range of 5.0 to 7.0.

Abstract: A stable rapidly dissoloving lyophilized and hydrated composition of cyclophosphamide and sodium bicarbonate is provided which contains an amount of water which is at least equimolar to the combined amount of cyclophosphamide and sodium bicarbonate in the composition and the weight ratio of cyclophosphamide to sodium bicarbonate is about 1:0.5 to 1:1.5; the composition is preferably prepared from a solution containing at least 1% (W/V) weight sodium bicarbonate.

Abstract: The compound (R) (-)-4-amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzo[b]furan-7-c arboxamide; the S isomer thereof, and pharmaceutical compositions containing the same.

Abstract: Pyrrolidinyl derivatives of Benzofuran-7-carboximides with analgesic activity".

Abstract: Benzofuran--7--carboxamides with anxiolytic activity.

Abstract: A pharmaceutical composition useful for treating hypercholesterolemia comprising a bile acid sequestrant resin such as cholestyramine and cholestipol maintained in a semipermeable water-insoluble material; wherein said semipermeable material enables bile acids from the digest tract to contact and bind to said resin while preventing substances having a higher molecular weight than bile acids from contacting said resin material. A method for treating hypercholesterolemia using the inventive composition is also disclosed.

Abstract: A stable rapidly dissolving lyophilized composition of cyclophosphamide and alanine is provided.

Abstract: A drug-protein conjugate of the general formula (I): ##STR1## where the moiety A--NH-- is the condensation product of an anticancer antibiotic having a free amino group, n is 0, 1 or 2, m is 0, 1, 2 or 3, the moiety --NHAB is the condensation product of a protein having a free amino group and the moiety ##STR2## is the condensation product of an amino acid of the formula HOOC--AA--NH.sub.2.

Abstract: A sustained release solid composition for delivering an amount of a pharmaceutical material, prticularly magnesium lactate, to the gastro-intestinal tract comprising:an active pharmaceutical powder material;a compressibility aid material for improving the compressibility of said pharmaceutical powder material;a first solid water soluble and/or swellable hydrophilic polymer; andmicrocrystalline cellulose to enable said active pharmaceutical material to be gradually released in the gastro-intestinal tract over a period of time;said solid composition being compressed in tablet form, and a method for producing the tablets is disclosed.

Abstract: The present invention is directed to a stable, rapidly soluble lyophilized injectable composition containing up to about 6% moisture and capable of being stored at room temperature comprising the hydrochloric or sulfate salt of a compound selected from the group consisting of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and (R)-(-)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione; wherein said lyophilized composition is prepared from a bulk solution comprising from about 25 mg/mL to about 40 mg/mL of said compound dissolved in a hydrochloric acid or sulfuric acid; wherein the pH of said bulk solution is from about 1.0 to about 2.0. The invention is further directed to an isotonic solution which is formed upon reconstitution of the lyophilizate of the invention with a pharmaceutically acceptable diluent.

Abstract: A process for preparing a compound of the formula (I) ##STR1## wherein R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen and methyl or R.sub.1 and R.sub.2 together represent an ethylene bridge group comprising:reacting a diamine of the formula (II)H.sub.2 N--CHR.sub.1 --CHR.sub.2 --NH.sub.2 (II)where R.sub.1 and R.sub.2 are defined as above with formaldehyde and an alkaline metal cyanide at a pH in the range of about 0 to 2 to produce a tetranitrile of the formula (III):(NCCH.sub.2).sub.2 N--CHR.sub.1 --CHR.sub.2 --N(CH.sub.2 CN).sub.2(III)hydrating said tetranitrile to yield an acid addition salt of a tetraamide of the formula (IV):(H.sub.2 NOCCH.sub.2).sub.2 N--CHR.sub.1 --CHR.sub.2 --N(CH.sub.2 CONH.sub.2).sub.2 .2HX (IV)where R.sub.1 and R.sub.

Abstract: A method for preparing a benzamide by reacting an aromatic acid with an amine having a primary amino group and a secondary amino group wherein the reaction is directed to the primary amino group by first reacting the acid with N,N'-carbonyldiimidazole.

Abstract: Carboxamides represented by the formula (I): ##STR1## wherein Z represents the carbon atoms necessary to complete a 5- to 7-membered ring,R.sup.1, R.sup.2, and R.sup.3 may be the same or different and are selected from the group consisting of a hydrogen atom, a lower alkyl group, a cycloalkyl group, a halogen atom, an amino group, a lower alkylamino group, an alkoxy group, an acylamido group, a sulfonamido group, and a nitro group; andA represents an aminoalkyl moiety and acid addition salts thereof.

Abstract: In a method for reconstituting dry fill cyclophosphamide, the vial volume is at least 50 ml and the headspace is at least 15 ml.

Abstract: A syringe purging device comprises a closed chamber into which air and/or any excessive amount of a hazardous liquid, such as a chemotherapy drug, is ejected from a syringe to overcome the health hazard created by openly purging syringes into the air or into a pad of gauze material. A sharp open end of a hollow needle of a syringe is sealingly inserted into the chamber and the syringe is activated to purge any air and/or excess liquid into the chamber which expands as necessary. Preferably, the chamber is then further expanded to reduce the pressure therewithin to better ensure clean withdrawal of the needle from the chamber or extension of the needle beyond the chamber and retention within the chamber of any fluids ejected from the syringe.

Abstract: A method for alleviating emesis caused by chemotherapy which comprises administering an antiemetic agent or a pharmaceutically acceptable salt thereof to a patient in conjunction with the administration of a chemotherapeutic agent, said antiemetic agent being represented by the formula (I) ##STR1## wherein Z represents a substituent such as a lower alkyl group, a methoxyethoxymethyl group, or a benzoylmethyl group; or Z in conjunction with the adjacent position represents the atoms necessary to complete a 5 to 7 membered saturated or unsaturated oxygen-containing ring; R represents a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, an amino group, an alkylsulfonyl group, a lower alkyl-substituted amino group, an acylamido group, a sulfamoyl group, a sulfonamido group or a nitro group; n is an integer of 1 to 3; W is a straight chain or branched chain alkylene group of 1 to 4 carbon atoms; and X represents the atoms necessary to complete a 5 or 6 membered ring; said

Abstract: A syringe purging device comprises a liquid-tight chamber into which air and/or any excessive amount of a hazardous liquid, such as a chemotherapy drug, is ejected from a syringe to overcome the health hazard created by openly purging syringes into the air or into a pad of gauze material. A sharp open end of a hollow needle of a syringe is sealingly inserted into the liquidtight chamber, and the syringe is activated to purge any air and/or excess liquid into the chamber. The liquidtight chamber may be closed, with any liquid ejected thereinto being retained by absorption into a wad of absorbent material contained within the chamber. Alternately, the chamber may be vented to the atmosphere through a hydrophobic filter such that air injected into the chamber passes through the filter, but any liquid is retained within the chamber since it cannot pass through the hydrophobic filter.